NuShu

NuShu Bio is a biotechnology company focused on developing innovative treatments for metabolic diseases, specifically obesity and type 2 diabetes. The company leverages a proprietary platform to create gut-restricted, non-systemic small molecules designed to trigger the body's natural metabolic signaling pathways without entering the bloodstream. By targeting receptors in the gastrointestinal tract, NuShu aims to provide the efficacy of systemic metabolic drugs while minimizing systemic side effects. The company is led by industry veterans with significant experience in metabolic drug development and is backed by prominent life science investors such as ARCH Venture Partners and F-Prime Capital.